{"id":2,"date":"2019-05-08T01:38:14","date_gmt":"2019-05-08T01:38:14","guid":{"rendered":"http:\/\/brinster.wpengine.com\/?page_id=2"},"modified":"2026-04-28T18:07:21","modified_gmt":"2026-04-28T18:07:21","slug":"sample-page","status":"publish","type":"page","link":"https:\/\/invest.fisherwallace.com\/","title":{"rendered":""},"content":{"rendered":"<p><!--\n\n<div style=\"width:100%;padding-top:20px;display:none;\">\n<script src=\"https:\/\/cdn.logwork.com\/widget\/countdown.js\"><\/script>\n<a onclick=\"return false;\" href=\"https:\/\/logwork.com\/countdown-8hva\" class=\"countdown-timer\" data-timezone=\"America\/New_York\" data-textcolor=\"#000000\" data-date=\"2025-12-15 23:59\" data-background=\"#04a4e7\" data-digitscolor=\"#ffffff\" data-unitscolor=\"#ffffff\">MAXIMUM BONUS SHARE OFFER ENDS IN:<\/a><\/div>\n\n--><\/p>\n<section id=\"1_header\" class=\"wrap1\">\n<p>&nbsp;<\/p>\n<div class=\"breakwrap\">\n<div class=\"left\"><img decoding=\"async\" class=\"corners\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/01\/oak_soldier.png\" alt=\"\"  \/><\/div>\n<div class=\"right\">\n<!--\n\n<p style=\"color: red;font-weight:bold\"\">Campaign has ended<br \/><a style=\"color: red; target=\"_blank\" href=\"https:\/\/fisherwallace.app.dealmaker.tech\/users\/sign_in\"><strong>Complete Your Investment<\/a> (if initiated by Feb 20th)<\/strong><\/p>\n\n--><br \/>\n<!--\n\n<h2><a href=\"\">ENDING TONIGHT: Invest in Fisher Wallace Labs<\/a><\/h2>\n\n\n\n\n<h2 style=\"font-weight: bold;\">OAK&reg;: A Resilience Multiplier for Veterans, First Responders, and the Armed Forces<\/h2>\n\n--><br \/>\n<!--\n\n\n<div style=\"width:100%;\"><script src=\"https:\/\/cdn.logwork.com\/widget\/countdown.js\"><\/script>\n<a onclick=\"return false;\" href=\"https:\/\/logwork.com\/countdown-8hva\" class=\"countdown-timer\" data-timezone=\"America\/New_York\" data-textcolor=\"#000000\" data-date=\"2024-10-17 23:59\" data-background=\"#04a4e7\" data-digitscolor=\"#ffffff\" data-unitscolor=\"#000000\">MAXIMUM BONUS SHARE OFFER ENDING IN:<\/a><\/div>\n\n\n--><\/p>\n<p>Invest in Fisher Wallace Laboratories, Inc.<\/p>\n<h2 style=\"font-weight: bold;\">FDA Clearance application submitted in April 2026<\/strong><br \/>\n(Clearance expected end of Summer 2026)<\/h2>\n<p>Perks for investing:<\/p>\n<ul class=\"list\">\n<li class=\"list\">100% Bonus Shares<\/li>\n<li class=\"list\">Invest $1502.90+ for Free OAK Coupon Code<\/li>\n<li class=\"list\">Minimum investment for bonus shares: $112.10 <sub>(+ 3.5% processing fee)<\/sub><\/li>\n<\/ul>\n<table style=\"margin: 20px 0 0 0 !important;\">\n<tbody>\n<tr>\n<td style=\"width: 200px;\"><a class=\"investBtn\" href=\"https:\/\/fisherwallace.app.dealmaker.tech\/invitations\/d9ddea20-565d-4ecb-b5d1-9022e6a1c6ae\/view\">INVEST<\/a><\/td>\n<td>\n<p style=\"font-size: 15px;\">Share Price $11.21<br \/>\n($11.60 including 3.5% fee)<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/1787792\/000178779226000005\/0001787792-26-000005-index.htm\" target=\"_blank\" rel=\"noopener\">SEC Filings<\/a>\u00a0|\u00a0<a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/1787792\/000178779226000005\/fwofferingcircularcf11.pdf\" target=\"_blank\" rel=\"noopener\">Form C<\/a>\u00a0|\u00a0<a href=\"#12_faq\" >Investor Education<\/a>\n<\/div>\n<p><!--close left-->\n<\/div>\n<p><!--close breakwrap--><br \/>\n<br clear=\"all\"><br \/>\n<\/section>\n<section id=\"2_problems\" class=\"wrap1\">\n<div class=\"breakwrap\">\n<h1>Problems at Scale<\/h1>\n<p><\/p>\n<p><!--<iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/LfdtzcWjd_I?rel=0;si=B0SoFomqAodsHDnI&amp;controls=0\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>--><img decoding=\"async\" class=\"corners\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/11\/adi_market.png\"><\/p>\n<p><a href=\"https:\/\/www.who.int\/news\/item\/02-09-2025-over-a-billion-people-living-with-mental-health-conditions-services-require-urgent-scale-up\" target=\"_blank\"><cite>Living with Mental Health Conditions<\/cite><\/a><br \/><a href=\"https:\/\/www.nami.org\/mental-health-by-the-numbers\/\" target=\"_blank\"><cite>Mental Health by the Numbers<\/cite><\/a><br \/><a href=\"https:\/\/news.va.gov\/137221\/va-2024-suicide-prevention-annual-report\/\" target=\"_blank\"><cite>Suicide Prevention Annual Report<\/cite><\/a><br \/>\n<!--\n\n<div class=\"flex-container2\">\n\n\n<div class=\"left\">\nAs many as 140 million Americans and 2.5 billion people globally have clinically significant symptoms of anxiety, depression and\/or insomnia.\n<\/div>\n\n\n\n\n<div class=\"right\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-232\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/iStock-2189360130.jpg\" alt=\"\" width=\"1255\" height=\"836\" srcset=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/iStock-2189360130.jpg 1255w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/iStock-2189360130-300x200.jpg 300w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/iStock-2189360130-1024x682.jpg 1024w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/iStock-2189360130-768x512.jpg 768w\" sizes=\"auto, (max-width: 1255px) 100vw, 1255px\" \/><\/div>\n\n\n<\/div>\n\n-->\n<\/div>\n<p><!--close breakwrap--><br \/>\n<\/section>\n<section id=\"3_mission\">\n<h1>Mission<\/h1>\n<p>To create a foundational brain-health hardware layer that restores and preserves emotional stability, cognitive resilience, and sleep at population scale.<\/p>\n<\/section>\n<section id=\"4_about\" class=\"wrap1\" style=\"background-color:hsl(198, 100%, 46%);color:white;\">\n<div class=\"breakwrap\">\n<div class=\"~flex-container2\" style=\"padding: 4% 0%;\">\n<h1>About Us<\/h1>\n<p>Fisher Wallace Labs makes scalable, wearable brain stimulation technology for the US government and large institutions, as well as for consumers and employers. 60,000 patients use our proof-of-concept device today to remain in remission from depression, anxiety and insomnia. Our next generation technology, OAK, was designed in collaboration with the teams behind Beats and Nest and is expected to receive initial FDA clearance by end of Summer 2026.<\/p>\n<p><!--<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/01\/woamn_blue_oak.png\" alt=\"\" width=\"1254\" height=\"1416\" class=\"corners alignnone size-full wp-image-277\" srcset=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/01\/woamn_blue_oak.png 1254w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/01\/woamn_blue_oak-266x300.png 266w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/01\/woamn_blue_oak-907x1024.png 907w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/01\/woamn_blue_oak-768x867.png 768w\" sizes=\"auto, (max-width: 1254px) 100vw, 1254px\" \/>--><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/04\/woamn_blue_oak_sm.png\" alt=\"\" width=\"600\" height=\"678\" class=\"corners alignnone size-full wp-image-292\" srcset=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/04\/woamn_blue_oak_sm.png 600w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/04\/woamn_blue_oak_sm-265x300.png 265w\" sizes=\"auto, (max-width: 600px) 100vw, 600px\" \/><\/p>\n<p>In 2025, researchers at Harvard Medical School demonstrated that our stimulation engages center-brain structures  integral to mood, sleep, and cognition. Over 1500 people have participated in clinical trials and real world studies that validate the safety and rapid, durable effectiveness of our technology when worn for 20 minutes, once or twice a day. No serious side effects have been reported in our clinical trials.<\/p>\n<p>Our technology is currently being studied in the U.S. Department of Veterans Affairs for the treatment of anxiety, and by a leading eSports team as tools for nervous system recovery and resilience. Prior research includes two published <a href=\"https:\/\/www.psychiatrist.com\/jcp\/remote-trial-transcranial-alternating-current-stimulation-for-depression\/\" target=\"_blank\">depression trials<\/a>, an anxiety study that is pending publication, an exploratory insomnia study, a published <a href=\"https:\/\/www.todaysmedicaldevelopments.com\/news\/medical-manufacturing-fisher-wallace-060612\/\" target=\"_blank\">Parkinson\u2019s study<\/a>, and real world studies of PTSD treatment and Substance Use Disorder rehabilitation.<\/p>\n<\/div>\n<\/section>\n<section>\n<h1>Version 1.0 Metrics<\/h1>\n<div class=\"row\">\n<div class=\"col\">\n<h2>Active Users<\/h2>\n<div class=\"counter\" data-start=\"0\" data-decimals=\"0\" data-duration=\"5\" data-suffix=\" +\" data-scroll=\"true\" data-end=\"60000\"><\/div><\/div>\n<div class=\"col\">\n<h2>Gross Revenue<\/h2>\n<div class=\"counter\" data-start=\"0\" data-decimals=\"0\" data-duration=\"5\" data-prefix=\"$\" data-suffix=\" +\" data-scroll=\"true\" data-end=\"40000000\"><\/div><\/div>\n<div class=\"col\">\n<h2>Prescribers<\/h2>\n<div class=\"counter\" data-start=\"0\" data-decimals=\"0\" data-duration=\"5\" data-suffix=\" +\" data-scroll=\"true\" data-end=\"14000\"><\/div><\/div>\n<\/div>\n<\/section>\n<section id=\"5_scientific\">\n<div class=\"flex-container2\">\n<div class=\"left\">\n<h1>Scientific Evidence<\/h1>\n<p>OAK treats symptoms by optimizing central brain function in 20 minutes daily. Research at Massachusetts General Hospital showed clinically significant electrical field delivery to the anterior cingulate cortex, hippocampus, amygdala, insula, and other regions integral to mood, sleep, and cognition. Clinical trials and real-world evidence show symptom reduction in the first week for most patients, without significant side effects.<\/p>\n<\/div>\n<div class=\"right\"><img decoding=\"async\" class=\"corners size-full wp-image-234\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/01\/brain_scan.png\" alt=\"\" \/><\/div>\n<\/div>\n<\/section>\n<section id=\"6_advancing\" class=\"wrap1\" style=\"~display:none;\">\n<div class=\"breakwrap\">\n<div class=\"flex-container2\">\n<div class=\"left\">\n<h1>Focus on Veterans<\/h1>\n<p>The US Department of Veterans started enrolling patients in a pilot study with our device in January 2026, at the Birmingham, Alabama VA medical Center. this study will serve as a &#8220;blueprint&#8221; for adoption for other medical centers, and we&#8217;ve selected Maclean Health as our VA and DoD marketing and distribution partner.\u00a0 With over a million veterans receiving mental health services every year,\u00a0 government procurement alone offers an opportunity for Fisher Wallace Labs to grow into a large enterprise by serving our nation&#8217;s heroes, while we methodically grow within the consumer mental healthcare market via telemedicine-powered eCommerce.<\/p>\n<\/div>\n<div class=\"right\"><img decoding=\"async\" class=\"corners alignnone size-full wp-image-228\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/01\/father_children.png\" alt=\"\"  \/><\/div>\n<\/div>\n<\/div>\n<p><!--close breakwrap--><br \/>\n<\/section>\n<section id=\"7_gen_z\">\n<div class=\"flex-container2\">\n<div class=\"left\">\n<h1>Gen Z<\/h1>\n<p>The highest mental health burden of any generation. OAK\u00ae addresses this with a rapid, comfortable, non-pharmacologic option designed for daily use and offered in vibrant colors. OAK\u00ae works rapidly but is designed for lifelong use and resilience.  People seen wearing it will much more likely be optimizing their brain performance than actively treating symptoms.<\/p>\n<\/div>\n<div class=\"right\"><img decoding=\"async\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/01\/oak_green.png\" alt=\"\" class=\"corners alignnone size-full wp-image-254\" \/><\/div>\n<p><br clear=\"all\">\n<\/div>\n<p style=\"margin-bottom:0;\">&nbsp;<\/p>\n<\/section>\n<section id=\"8_interest\" class=\"wrap1\" style=\"background-color:hsl(198, 100%, 46%);color:white;\">\n<div class=\"breakwrap flex-container2\">\n<div class=\"left\">\n<h1>FDA Clearance Application Submitted<\/h1>\n<p>We partnered with leading consultancy Healthcare Innovation Catalysts to prepare and submit our FDA clearance application for the treatment of anxiety and to manage FDA questions during review. Contrary to common public assumption, the FDA\u2019s device division is designed for relatively rapid review and generally caps substantive review time for 510(k) submissions at 90 FDA days, with decisions often issued sooner. Our application is further supported by the FDA\u2019s prior regulation of our Version 1.0 device over many years and by the strong results of our recent anxiety trial.<\/p>\n<\/div>\n<div class=\"right\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/09\/oak_latest_crop.png\" alt=\"\" width=\"500\" height=\"500\" class=\"corners alignnone size-full wp-image-255\" \/><\/div>\n<\/div>\n<p><br clear=\"all\">\n<\/div>\n<\/section>\n<section id=\"8_interest\" style=\"display:none;\">\n<div class=\"flex-container2\">\n<div class=\"left\">\n<h1>In the National Interest<\/h1>\n<p>Brain performance and resilience are essential to national security and public safety. As companies like Palantir and Anduril strengthen U.S. hardware and operational software capabilities across the defense and other sectors, Fisher Wallace is focused on strengthening human capabilities.<\/p>\n<p>Read the Substack by our Co-Founder and CEO, Kelly Roman<\/p>\n<p>We are currently scoping US contract manufacturing opportunities to manufacture devices for the US government. <\/p>\n<\/div>\n<div class=\"right\"><img decoding=\"async\" class=\"corners alignnone size-full wp-image-228\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2026\/01\/father_children.png\" alt=\"\"  \/><\/div>\n<\/div>\n<\/section>\n<section id=\"9_advisors\" class=\"wrap1\">\n<div class=\"breakwrap\">\n<h1>Advisors<\/h1>\n<div class=\"left\"><img loading=\"lazy\" decoding=\"async\" style=\"max-width:50%\" class=\"alignnone size-full wp-image-231\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/Dr.-Maurizio-Fava.jpg\" alt=\"\" width=\"460\" height=\"460\" srcset=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/Dr.-Maurizio-Fava.jpg 460w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/Dr.-Maurizio-Fava-300x300.jpg 300w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/Dr.-Maurizio-Fava-150x150.jpg 150w\" sizes=\"auto, (max-width: 460px) 100vw, 460px\" \/><\/p>\n<p><strong>Dr. Maurizio Fava<\/strong><br \/>\nPsychiatrist-in-Chief, Massachusetts General Hospital<br \/>\nChair, Mass General Brigham Academic Medical Centers Psychiatry Department<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" style=\"max-width:50%;filter: grayscale(100%);\" class=\"alignnone size-full wp-image-230\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/shulkin_david-landscape_2-e1758813255924.jpg\" alt=\"\" width=\"460\" height=\"460\" srcset=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/shulkin_david-landscape_2-e1758813255924.jpg 400w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/shulkin_david-landscape_2-e1758813255924-300x300.jpg 300w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2025\/09\/shulkin_david-landscape_2-e1758813255924-150x150.jpg 150w\" sizes=\"auto, (max-width: 460px) 100vw, 460px\" \/><\/p>\n<p><strong>Dr. David Shulkin<\/strong><br \/>\nFmr US Secretary of Veterans Affairs<br \/>\nFmr CEO of Beth Israel Medical Center<br \/>\nBoard Member, Maclean Health<\/p>\n<\/div>\n<p><br clear=\"all\"><br \/>\n<!--close breakwrap--><br \/>\n<\/section>\n<section id=\"10_founders\">\n<h1>Co-Founders<\/h1>\n<p><img loading=\"lazy\" decoding=\"async\" style=\"max-width:50%\" class=\"alignnone size-full wp-image-141\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/01\/kr.png\" alt=\"\" width=\"443\" height=\"512\" srcset=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/01\/kr.png 443w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/01\/kr-260x300.png 260w\" sizes=\"auto, (max-width: 443px) 100vw, 443px\" \/><br \/>\n<strong>Kelly Roman<\/strong><br \/>\nCo-Founder and CEO<br \/>\n17 years of neurotech leadership, published author, Harvard College graduate, son of U.S. Army Veteran<br \/>\n<img loading=\"lazy\" decoding=\"async\" style=\"max-width:50%\" class=\"alignnone size-full wp-image-137\" src=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/01\/cf.png\" alt=\"\" width=\"400\" height=\"400\" srcset=\"https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/01\/cf.png 400w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/01\/cf-300x300.png 300w, https:\/\/invest.fisherwallace.com\/wp-content\/uploads\/2024\/01\/cf-150x150.png 150w\" sizes=\"auto, (max-width: 400px) 100vw, 400px\" \/><br \/>\n<strong>Charles \u201cChip\u201d Fisher<\/strong><br \/>\nCo-Founder and Chairman<br \/>\nAngel investor in Fisher Wallace Labs, Philanthropist, Harvard College graduate, Juilliard Board Member\n<\/div>\n<\/section>\n<section id=\"12_faq\" class=\"wrap1\" style=\"scroll-margin-top:80px;\">\n<div class=\"breakwrap\">\n<h1>Frequently asked questions<\/h1>\n<div class=\"left\">\n<details>\n<summary>1. Why invest in startups?<\/summary>\n<p>Regulation CF allows investors to invest in startups and early-growth companies. This is different from helping a company raise money on Kickstarter; with Regulation CF Offerings, you aren\u2019t buying products or merchandise &#8211; you are buying a piece of a company and helping it grow.<\/p>\n<\/details>\n<details>\n<summary>2. How much can I invest?<\/summary>\n<p>Accredited investors can invest as much as they want. But if you are NOT an accredited investor, your investment limit depends on either your annual income or net worth, whichever is greater. If the number is less than $124,000, you can only invest 5% of it. If both are greater than $124,000 then your investment limit is 10%.<\/p>\n<\/details>\n<details>\n<summary>3. How do I calculate my net worth?<\/summary>\n<p>To calculate your net worth, just add up all of your assets and subtract all of your liabilities (excluding the value of the person\u2019s primary residence). The resulting sum is your net worth.<\/p>\n<\/details>\n<details>\n<summary>4. What are the tax implications of an equity crowdfunding investment?<\/summary>\n<p>We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.<\/p>\n<\/details>\n<details>\n<summary>5. Who can invest in a Regulation CF Offering?<\/summary>\n<p>Individuals over 18 years of age can invest.<\/p>\n<\/details>\n<details>\n<summary>6. There will always be some risk involved when investing in a startup or small business.<\/summary>\n<p>The earlier you invest, the more risk that is usually present. If a company goes out of business, your ownership interest could lose all value. Your\u00a0shares may not have voting rights or you may have limited voting power to direct the company due to dilution over time. You may have to wait five to seven years (if ever) for an exit via acquisition, IPO, etc. Because early-stage companies are still in the process of perfecting their products, services, and business model, nothing is guaranteed. That\u2019s why startups should only be part of a more balanced, overall investment portfolio.<\/p>\n<\/details>\n<details>\n<summary>7. The Common Stock (the \u201cShares\u201d) of Fisher Wallace Laboratories (the \u201cCompany\u201d) is not publicly-traded.<\/summary>\n<p>As a result, the shares cannot be easily traded or sold. As an investor in a private company, you typically look to receive a return on your investment under the following scenarios: (i) the Company gets acquired by another company, or (ii) the Company goes public (makes an initial public offering). In those instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on an exchange. These are both considered long-term exits, taking approximately 5-10 years (and often longer) to see the possibility for an exit. It can sometimes take years to build companies. Sometimes there will not be any return as a result of business failure. Shares sold via Regulation Crowdfunding offerings have a one-year lockup period before those shares can be sold under certain conditions.<\/p>\n<\/details>\n<details>\n<summary>8. Exceptions to limitations on selling shares during the one-year lockup period:<\/summary>\n<p>In the event of death, divorce, or similar circumstance, shares can be transferred to:<br \/>\n\u2022 The company that issued the securities<br \/>\n\u2022 An accredited investor<br \/>\n\u2022 A family member (child, stepchild, grandchild, parent, stepparent, grandparent, spouse or equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships)<\/p>\n<\/details>\n<details>\n<summary>9. What happens if a company does not reach their funding target?<\/summary>\n<p>If a company does not reach their minimum funding target, all funds will be returned to the investors after the close of the offering.<\/p>\n<\/details>\n<details>\n<summary>10. How can I learn more about a company&#8217;s offering?<\/summary>\n<p>All available disclosure information can be found on the offering pages for our Regulation Crowdfunding offering.<\/p>\n<\/details>\n<details>\n<summary>11. What if I change my mind about investing?<\/summary>\n<p>You can cancel your investment at any time, for any reason, until 48 hours prior to a closing occurring. If you\u2019ve already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email: info@dealmakersecurities.com<\/p>\n<\/details>\n<details>\n<summary>12. How do I keep up with how the company is doing?<\/summary>\n<p>At a minimum, the company will be filing with the SEC and posting on it\u2019s website an annual report, along with certified financial statements. Those should be available 120 days after the fiscal year end. If the company meets a reporting exception, or eventually has to file more reported information to the SEC, the reporting described above may end. If these reports end, you may not continually have current financial information about the company.<\/p>\n<\/details>\n<details>\n<summary>13. What relationship does the company have with DealMaker Securities?<\/summary>\n<p>Once an offering ends, the company may continue its relationship with DealMaker Securities for additional offerings in the future. DealMaker Securities\u2019 affiliates may also provide ongoing services to the company. There is no guarantee any services will continue after the offering ends.<\/p>\n<\/details>\n<\/div>\n<div class=\"right\"><\/div>\n<p>&nbsp;<\/p>\n<\/div>\n<p><br clear=\"all\"><br \/>\n<!--close breakwrap--><\/p>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; Invest in Fisher Wallace Laboratories, Inc. FDA Clearance application submitted in April 2026 (Clearance expected end of Summer 2026) Perks for investing: 100% Bonus Shares Invest $1502.90+ for Free OAK Coupon Code Minimum investment for bonus shares: $112.10 (+ 3.5% processing fee) INVEST Share Price $11.21 ($11.60 including 3.5% fee) SEC Filings\u00a0|\u00a0Form C\u00a0|\u00a0Investor Education [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"open","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-2","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/invest.fisherwallace.com\/index.php?rest_route=\/wp\/v2\/pages\/2","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/invest.fisherwallace.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/invest.fisherwallace.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/invest.fisherwallace.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/invest.fisherwallace.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2"}],"version-history":[{"count":0,"href":"https:\/\/invest.fisherwallace.com\/index.php?rest_route=\/wp\/v2\/pages\/2\/revisions"}],"wp:attachment":[{"href":"https:\/\/invest.fisherwallace.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}